Split History
ETFs Holding MTEM »    MTEM Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Molecular Templates is a clinical-stage oncology company focused on the discovery and development of biologic therapeutic for cancer. Co. utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies (ETBs). Co. has developed ETBs for various targets, including CD20, CD38, HER2, and PD-L1. CD20 is central to B cell malignancies and is clinically validated as a target for the treatment of lymphomas and autoimmune disease. CD38 has been validated as a clinical target in the treatment of various myeloma. PD-L1 is central to immune checkpoint pathways and is a target expressed in a variety of solid tumor cancers. According to our MTEM split history records, Molecular Templates has had 1 split.
MTEM split history picture
Molecular Templates (MTEM) has 1 split in our MTEM split history database. The split for MTEM took place on August 02, 2017. This was a 1 for 11 reverse split, meaning for each 11 shares of MTEM owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 90.9090909090909 share position following the split.

When a company such as Molecular Templates conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share. Looking at the MTEM split history from start to finish, an original position size of 1000 shares would have turned into 90.9090909090909 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Molecular Templates shares, starting with a $10,000 purchase of MTEM, presented on a split-history-adjusted basis factoring in the complete MTEM split history. MTEM split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 11/16/2009
End date: 11/13/2019
Start price/share: $22.11
End price/share: $7.18
Dividends collected/share: $0.00
Total return: -67.53%
Average Annual Total Return: -10.64%
Starting investment: $10,000.00
Ending investment: $3,247.62
Years: 10.00
Date Ratio
08/02/20171 for 11
MTEM is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

MYG Split History
MYGN Split History
MYL Split History
NAVB Split History
NBS Split History
NBY Split History
NEOG Split History
NNVC Split History
NRCIB Split History
NSPH Split History

Also explore: MTEM shares outstanding history

TRACON Pharmaceuticals (TCON)
SELLAS Life Sciences Group, Inc. (SLS)
Tonix Pharmaceuticals Holding Corp. (TNXP)
Camber Energy, Inc. (CEI)
Cancer Genetics, Inc. (CGIX)
Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 3X Shares (GUSH)
Kingold Jewelry, Inc. (KGJI)
Aethlon Medical, Inc. (AEMD)
Aberdeen Standard Physical Gold Shares ETF (SGOL)
Safe-T Group Ltd. (SFET)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

MTEM Insider Buying

MTEM Split History | www.SplitHistory.com | Copyright © 2013 - 2019, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.